CELLVIE CEO Dr. Alexander Schueller was awarded the prestigious De Vigier Award

cellvie AG is proud to announce that CEO Dr. Alexander Schueller was awarded the prestigious De Vigier Entrepreneurship Award.

The W.A. de Vigier Foundation promotes and supports innovative entrepreneurial spirit in Switzerland. Since 1987, the goal of the foundation has been to invigorate emerging companies, providing support to young entrepreneurs, who stand out in the country's innovation-rich startup environment. Today, the De Vigier Award is one of the most respected prizes for young entrepreneurs in Switzerland, being awarded for especially high degrees of innovation, value creation for society as a whole, and the technical and financial viability of the founders' company.

Every year, entrepreneurs can submit an application for the chance to pitch their idea, project, or company to a jury, in the hopes of reaching the final round with the possibility of winning CHF 100,000. Due to Covid-19 regulations, this year's first De Vigier Award selection round was held digitally. Out of >200 applications 60 entrepreneurs were selected to present to the De Vigier Foundation jury. Only 17 advanced to the final round, of which 12 were chosen as finalists.

cellvie is proud to announce that Alex Schueller, the company's CEO and co-founder, was not only one of these 12 bright minds, invited to showcase their innovations in person, but prevailed amid fierce competition. He was selected as one of six to receive the De Vigier Award's grand prize. The CHF 100,000 contribution will be used to further cellvie's work in Therapeutc Mitochondria Transplantation.

Alex founded cellvie together with Drs. James McCully, Pedro del Nido and Sitaram Emani. Born in Germany, he studied business at the Maastricht University in The Netherlands, before joining The Boston Consulting Group. In the subsequent pursuit of his PhD, he came across a unique surgical glue technology, upon which he co-founded Adhesys Medical. This first venture of his was acquired by the Grunenthal Group in 2017. With cellvie, Alex is particularly excited about the chance to contribute to what may emerge as a new treatment modality: the therapeutic use of mitochondria.

Alex's presentation at the award ceremony can be watched here:

About cellvie AG

Started in the US and headquartered in Zürich, Switzerland, cellvie is developing medicines from cells, leveraging the therapeutic potential of mitochondria. The company was founded by Drs. Schueller, McCully, del Nido and Emani in 2018. Dr. McCully pioneered the approach of mitochondria augmentation and replacement at Harvard Medical School and the team has now set out to bring it about as a new treatment modality in ischemia-reperfusion injury, aging, and beyond. Since its founding cellvie has successfully expanded its team and operations close to Zürich.

Further information can be found at www.cellvie.bio.

Back to news